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ABSTRACT 
Testing the Effect of Ketamine on Recovery and as an Antidepressant in an Spinal Cord 
Contusion Model 
Kayla Nguyen    
Department of Biology 
Texas A&M University 
Nishah Panchani 
Department of Biomedical Sciences 
Texas A&M University 
Research Advisor: Dr. Michelle Hook 
Department of Neuroscience 
In addition to the physical effects, spinal cord injury (SCI) also impacts quality of life and 
psychological wellbeing. Compared to the rate of 8.6% in the general population, the incidence 
of major depressive disorder (MDD) ranges from 11 to 24% in SCI patients (Krause et al., 2000). 
 Currently, depression after SCI is treated with selective serotonin reuptake inhibitors (SSRIs), 
but these drugs have side effects that include attenuation of functional recovery after SCI (Coyle 
et al., 2015).  
S-Ketamine is a novel drug that has shown potential as an antidepressant, but has not been 
assessed following SCI. To address this, we used a battery of established behavioral tests 
(sucrose preference, forced swim, open-field activity, social exploration, and burrowing tasks) to 
assess depression in a rodent SCI model. Subjects were acclimated to the behavioral tasks and 
baseline scores were collected two days before a moderate contusion injury. Twenty-four hours 
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later, subjects were given an injection of 0, 5, 10, or 20 mg/kg S-ketamine (i.p.). Depression was 
re-assessed on days 2, 9-10, and 19-21 post-injury.  
To characterize subjects as depressed or not-depressed, initial analyses focused on data collected 
on days 9-11 and 19-21 post-injury, after any potential antidepressant effects of S-ketamine 
should have dissipated. Using cluster analyses, we found that 13 out of 32 subjects (41%) 
displayed depression-like behaviors (decreased sucrose preference and open-field activity). Next, 
we examined the effects of S-ketamine. Analyzing data collected on day 2 post-injury, and within 
the window for S-ketamine’s efficacy, we found that 20 mg/kg ketamine increased social 
behavior, relative to all other dose groups. Importantly, depressed subjects treated with 20 mg/kg 
S-ketamine showed the highest level of social interaction 24 hours after administration. These 
data suggest that S-ketamine may be an effective antidepressant after SCI. Further studies are 
warranted to elucidate the molecular mechanisms mediating these effects and to optimize 
administration schedules.  
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CHAPTER I  
  INTRODUCTION 
 
Spinal cord injury  
In the United States alone, approximately 276 000 individuals live with a spinal cord injury 
(SCI), with 12 500 new cases occurring every year (NSCISC, 2015). The majority (82%) of SCI 
patients are males, with injury occurring most often between the ages of 16-30 years. Depending 
on the severity of the injury, and the vertebral level at which it occurs, SCI will result in 
paralysis, loss of sensory function, loss of bowel or bladder control, dysreflexia or spasms, loss 
of sexual function/sensitivity and fertility, chronic pain, and difficulty breathing, coughing, or 
clearing secretions from the lungs. 
In addition to physical effects, SCI decreases quality of life and impacts psychological wellbeing. 
Compared to the rate of 8.6% in the general population, the incidence of major depressive 
disorder (MDD) ranges from 11 to 24% in patients after SCI (Krause et al., 2000).  Decreased 
psychological wellbeing is one of the most significant, and often overlooked, consequences of 
injury. The significance of depression on quality of life is underscored by data showing that 
suicidal ideation and attempts are three times greater in the SCI population, relative to the non-
injured population (Teasdale et al., 2001). Depression also has significant implications for 
physical recovery post SCI. For example, the incidence of urinary tract infections, pressure 
ulcers, autonomic dysreflexia, and acute, uncontrolled hypertension are significantly increased in 
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SCI patients with depression, relative to non-depressed patients (Al Taweel et al., 2015).  
Depression significantly affects the wellbeing and recovery of SCI patients.  
Diagnosis of depression 
According to the American Psychiatric Association (DSM-IV-TR, 2000), MDD is diagnosed 
when at least five of the following symptoms are observed for at a two-week period minimum 
(DSM-IV-TR, 2000). In all cases, individuals either experience a depressed mood or a loss of 
interest or pleasure.  
Symptoms of major depressive disorder include (DSM-IV-TR, 2000): 
1. Depressed mood most of the day, nearly every day  
2. Markedly diminished interest or pleasure in all, or almost all, activities most of the 
day, nearly every day  
3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 
5% of body weight in a month), or decrease or increase in appetite nearly every day 
4. Insomnia or hypersomnia nearly every day 
5. Psychomotor agitation or retardation nearly every day  
6. Fatigue or loss of energy nearly every day 
7. Feelings of worthlessness or excessive or inappropriate guilt  
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either 
by subjective account or as observed by others) 
9. Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a 
suicide attempt or a specific plan for committing suicide 
Although not all patients meet the criteria for MDD, 37% display significant symptoms of 
depression after SCI (Migliorini et al., 2009). Antidepressant drug therapy is commonly 
prescribed for these individuals (Siddal et al., 2015). Unfortunately, however, frequently 
prescribed selective serotonin reuptake inhibitors (SSRI) do not reverse all signs of depression 
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and have side effects that can include attenuation of functional recovery, as well as a paradoxical 
potentiation of symptoms of depression (Coyle et al., 2015). Moreover, current antidepressants 
act on the monoamine systems of the brain and are slow to elicit antidepressant effects (Anisman 
et al., 2009). There is also evidence that these treatments may attenuate recovery of function for 
patients. For example, Fullerton (1981) reported that 3 SCI patients were diagnosed with major 
depression and treated with amitriptyline. Two of the patients developed adverse side effects 
(including autonomic dysreflexia), and the remaining individual improved by discharge from the 
inpatient rehabilitation program rather than the anti-depressant treatment itself (Fullerton et al., 
1981).  
Notably, studies also indicate that 23% of patients suffer intractable depression (Zorumski et al., 
2015), which means that they do not experience relief from depression irrespective of the 
treatments prescribed. In fact, they often feel discouraged after seeing no significant results and 
this can worsen their mental condition. Therefore, further research on the etiology of depression 
and its interaction with SCI, as well as the molecular effects of conventional 
pharmacotherapeutics, is needed. The development of animal models is essential for elucidating 
the molecular causes of depression following SCI. To address this, the current study tested the 
potential of S-ketamine, as an antidepressant, in an animal model of SCI.  
A rodent model of depression after spinal cord injury 
Tests for behaviorally assessing depression have been developed for rodent models of various 
different disease or injury states, including epilepsy (Jones et al., 2008), traumatic brain injury 
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(Fromm et al., 2004), Parkinson’s (Itier et al., 2003), cancer (Lamkin et al, 2010; Pyter et al., 
2009), cholestasis (Swain and Le, 1998), diabetes (Hilakivi-Clarke et al., 1990) and stroke 
(Wang et al., 2009). The behaviors measured in these paradigms are analogous to some, though 
not all, of the core symptoms of major depressive disorder (outlined in Table 1), including 
‘helplessness’, loss of interest in pleasurable activities, and decreases in activity or changes in 
appetite and sleep patterns.  Indeed, McKinney and Bunney (1969) indicated that valid animal 
models of depression should: 
1. Have induced symptoms of depression that are reasonably analogous to those seen in 
human depression. 
2. Have observable behavioral changes, which can be objectively evaluated. 
3. Independent observers should agree on objective criteria for drawing conclusions on 
the subjective state. 
4. The treatment modalities effective in reversing depression in humans should reverse 
the changes seen in animals. 
5. The system should be reproducible by other investigators 
 Addressing these criteria, Luedtke et al. (2011) recently validated a behavioral ethogram for 
assessing depression in an animal model of SCI. Using established behavioral tests for 
depression, Luedtke et al. (2011) found that 35% of rats with SCI exhibited symptoms of 
depression, an incidence commensurate with SCI patients reporting clinical symptoms of 
depression without a diagnosis of MDD (Migliorini et al., 2009). Subjects that clustered in the 
“depressed” group displayed a loss of interest or pleasure; they had significantly lower 
preferences for sucrose, decreased social exploration, and increased immobility in the forced 
swim test, which signifies helplessness, compared to “non-depressed” rats.  Depressed rats also 
displayed psychomotor retardation, demonstrating significantly reduced exploratory and 
pleasurable activities when compared to their non-depressed counterparts (Luedtke et al., 2011).  
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Further validating this model of depression, Luedtke et al. (2011) demonstrated that a clinically-
relevant antidepressant, fluoxetine, reversed depressive symptoms in the forced swim test. Thus, 
the pharmacological therapies effective at reversing depression in humans were also efficacious 
in the depressed SCI rats. These data are important as they demonstrate that even in the absence 
of the confounding psychosocial variables (i.e. loss of independence, economical stressors) the 
molecular changes inherent to SCI exacerbate depression in rodents and may impact 
psychological wellbeing in humans. 
Meeting the 5th criterion for an animal model of depression, evidence of depression after SCI has 
been reported by independent laboratories. Using the procedures outlined by Luedtke et al. 
(2011), Maldonado et al. (2016) examined depression in a rodent SCI model to test the 
relationship between inflammation and depression/anxiety post injury. The data from this study 
supported the hypothesis that changes in molecular mediators of inflammation are associated 
with decreased psychological wellbeing following SCI. In an independent laboratory, Wu et al. 
(2014) used a similar animal model to find that SCI caused spatial and retention memory 
impairment and depressive-like behavior. Therefore, these independent laboratories were able to 
see evidence of depression using similar models. Thus, the criteria for accessing depression in 
our rodent injury model has been met and will be used to test for S-ketamine as a potential 
antidepressant following SCI.  
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S-Ketamine as an anti-depressant following spinal cord injury 
Currently, depression after SCI is treated with SSRI’s. These medications, however, do not 
reverse all signs of depression and have potential side effects that include attenuation of 
functional recovery as well as the paradoxical potentiation of symptoms of depression (Coyle, et 
al., 2015). Moreover, the efficacy of current pharmacological treatments differs not only across 
patients, but also across injury and disease conditions (i.e. SCI and post-traumatic stress 
disorder). It is likely that there are diverse molecular changes that underlie the multi-faceted 
symptoms of depression. New and effective treatments must also be developed. Indeed, the 
incidence of intractable depression in the human population underscores the need for the 
development of alternative anti-depressant therapies. 
  
In recent years, ketamine has shown potential as an anti-depressant for MDD (Coyle and Laws 
2015).  In contrast to commonly prescribed anti-depressants, ketamine is an N-methyl-D-
aspartate antagonist, thereby affecting the action of glutamate a major excitatory 
neurotransmitter in the brain (aan het Rot et al., 2012), with purported rapid antidepressant 
properties that are sustained beyond ketamine’s 3-hour half-life (Young, 2013; Salvadore and 
Singh, 2013). In a meta-analysis, Coyle and Laws (2015) reviewed the results of 21 different 
experiments using ketamine as an anti-depressant for MDD and bipolar disorder (BO). This 
meta-analysis showed that ketamine reduced depressive symptoms, at variable time points in 
patients with MDD and BO (Coyle and Laws, 2015).  
	     	   	  11
In research with SCI patients, ketamine has also shown effectiveness in managing neuropathic 
pain and allodynia (an experience of pain from a non-painful stimulation of the skin) (Tam et al., 
2012). Since pain is often comorbid with depression (Nicholson et al., 2009), indicating that it 
may lead to the development of depression or vice versa, ketamine may also be useful in treating 
depression after SCI. From a molecular perspective, one of the key changes associated with the 
pain and depression is an increase in pro-inflammatory cytokines post injury (Maldonado et al., 
2016). Research indicates that ketamine has neuroprotective and anti-inflammatory effects post-
SCI, reducing the over-expression of inflammatory cytokines such as IL-6 (Niesters et al., 2014). 
We hypothesize that ketamine, by reducing levels of pro-inflammatory cytokines such as IL-1β 
and IL-6 mRNA, may be an effective treatment for depression after SCI, as well as recovery post 
injury (Bette et al., 2004). To date, however, no research has directly assessed the effects of 
ketamine on depression following SCI. 
Importantly, despite the purported benefits of ketamine treatment it is also possible that it will 
have adverse effects in SCI patients. Ketamine is a dissociative psychedelic drug (Muetzelfeldt et 
al., 2008). Consequently, ketamine also has the potential to cause hallucinations and to possibly 
exacerbate anxiety symptoms that are linked to depression in many patients (Irwin et al., 2013).  
The effects of ketamine must be empirically assessed in an SCI model. Thus, the proposed 
experiment will test the effects of S-ketamine in the rodent SCI model, comparing the 
manifestation of depression-like symptoms in subjects treated with S-ketamine and vehicle-
treated controls. We will examine the effects of S-ketamine, rather than ketamine, in the rodent 
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SCI model because it is the stronger NMDA antagonist between the R and S isomers, with twice 
the analgesic potency compared to the clinically used racemic mixture (Muller et. al., 2016).  
Table 1. Symptoms of Major Depressive Disorder and Corresponding Measure for 
Symptom-like Behavior in Rats 
Depression Symptom in the       
DSM-IV-TR
Measure of Symptom-
Like Behavior in Rats
         References
Recurrent thoughts of death, 
recurrent suicidal ideation 
without a specific plan, or a 
suicide attempt or a specific plan
Forced Swim Test
Pyter et al., 2009 
Hilakivi et al., 1990
Feelings of worthlessness or 
excessive or inappropriate guilt
Not applicable
Markedly diminished interest or 
pleasure 
Sucrose Preference Test 
Social Exploration
Jones et al., 2008; 
Lamkin et al., 2010; 
Wang et al., 2008; 
Pyter et al., 2009 
Overstreet et al., 2010 
Swain and Le, 1998
Significant weight loss when not 
dieting or weight gain or 
decrease or increase in appetite 
Monitor subject weight 
and food consumption
Itier et al., 2003 
Lamkin et al., 2010
Psychomotor agitation or 
retardation 
Open Field Test 
Stressor Recognition 
Test
Fromm et al., 2004; 
Jones et al., 2007; 
Wang et al., 2009; 
Itier et al., 2003; 
Lamkin et al., 2011
Fatigue or loss of energy Burrowing Deacon, 2006 
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CHAPTER II 
METHODS 
Subjects 
Subjects were male Sprague-Dawley rats (Harlan, Houston, TX) between 90-110 days old. They 
were individually housed in Plexiglas bins (45.7 (length) x 23.5 (width) x 20.3 (height) cm) with 
ad libitum food and water. Food consumption and subject weights were recorded daily. Until 
subjects regained full bladder control, they were manually expressed in the morning (8-9:30 
a.m.), and in the evening (5:30-7:00 p.m.). They were maintained on a 12 hour light/dark cycle 
and all behavioral testing was conducted during the light cycle. All of the experiments were 
reviewed and approved by the institutional animal care committee at Texas A&M University, and 
all NIH guidelines for the care and use of animal subjects were followed. 
Surgery 
Subjects received a moderate contusion injury using the Infinite Horizon spinal cord impactor 
(PSI, Fairfax Station, VA). Briefly, subjects were anesthetized with isoflurane (5%, gas), and 
after a stable level of anesthesia was reached, the concentration of isoflurane was lowered to 
2-3%.  The subject’s back was shaved and disinfected with iodine and a 5.0 cm incision was 
made over the spinal cord. Two incisions were made on the vertebral column on each side of the 
dorsal spinous processes, extending about 2 cm rostral and caudal to the T12 segment. Muscle 
and connective tissue were then dissected to expose the underlying vertebral segments. 
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Musculature around the transverse processes was cleared to allow for clamping of the vertebral 
spinal column. Next, the dorsal spinous process at T12 was removed (laminectomy), and the 
spinal tissue exposed. The dura remained intact. The vertebral column was fixed within the IH 
device using two pairs of Adson forceps. A moderate injury was produced using an impact force 
of 150 kilodynes and a 1 s dwell time. After injury, the wound was closed using Michel clips. To 
help prevent infection, subjects were treated with 100 000 units/kg Pfizerpen (penicillin G 
potassium) immediately after surgery and again 2 days later. For the first 24 h after surgery, rats 
were placed in a recovery room maintained at 26.6 °C. To compensate for fluid loss, subjects 
were given 3 ml of saline after surgery. Michel clips were removed 14 d after surgery. 
S-ketamine administration 
Drug administration occurred 24 h following SCI. First, baseline locomotor function was 
determined using the Basso, Beattie, and Bresnahan (BBB) scale (Basso et al. 1995). Balancing 
BBB scores across groups, subjects were then assigned to one of four treatment conditions: 0, 5, 
10, and 20 mg/kg of S-ketamine obtained from Cristalia Produtos Quimicos Farmaceuticos 
Ltda., (San Paulo, Brazil). Drug was administered via an intraperitoneal (i.p.) injection. An 
equivalent volume of filtered 0.9% saline was administered to vehicle controls. To evaluate the 
analgesic efficacy of S-ketamine, sensory reactivity was assessed before drug treatment and 30, 
60, 120 and 180 min post-treatment using the von Frey and tail-flick tests (described below). 
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Assessment of depression 
The following time schedule was used in all experiments (Figure 1). Tests of depression 
evaluated symptoms analogous to those observed in human patients (Table 1). All testing took 
place during the light cycle. On days in which more than one test was conducted, subjects were 
returned to their home cages after the first test for a minimum of two hours before beginning the 
second test. 
Sucrose preference test 
The sucrose preference test can be used to test for anhedonia- a loss of interest in pleasurable 
activities. Anhedonia is a core symptom of MDD. Rats exhibiting anhedonia display a decreased 
preference for a sucrose solution over plain water, when compared to baseline measures taken 
prior to injury or disease. Sucrose preference tests were conducted in the subject’s home cage. 
For testing, one pre-weighed water bottle filled with approximately 200 mL of 2% sucrose 
solution and a pre-weighed bottle filled with an equal amount of filtered water were placed on 
either side of the subject’s cage, and left for 2 hours. The placement of the sucrose and the water 
solutions on either the left or right sides was counterbalanced between subjects. The position of 
the bottle (left/right) was reversed halfway through the 2-hour period, to prevent any positional 
biases from confounding results. At the end of the 2-hour test period, the change in the weight of 
each bottle was determined. The absolute sucrose intake per gram of rat body weight and sucrose 
preference (SP) was then calculated using the following formula: SP = sucrose solution intake 
(mL) / [sucrose solution intake (g) + water intake (g)] (Wang et al., 2009). Baseline sucrose 
preference levels were assessed three days prior to injury. Following injury, sucrose preference 
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was assessed on days 2, 9, and 19. Subjects were assigned a set of bottles during the acclimation 
period and used the same set for each of the testing periods. 
!  
Figure 1. Experiment Schedule 
Open field activity 
Since rats are naturally social and curious animals, the open field test is a simple measure for the 
depressive-like symptom of decreased interest or pleasure-seeking. When placed in a large open 
field environment, rats with symptoms of depression will display decreased locomotor activity 
and reduced exploratory behavior.  
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The open-field environment was a black plywood box [100 (length) x 50 (height) x 100 (width) 
cm]. The floor of the box was partitioned into 100 squares [10 (length) x 10 (width) cm] 
delineated with a silver marker. A layer of clear Plexiglas was used to cover the top of the box. 
Subjects were acclimated to the testing room for 10 minutes prior to testing. The testing room 
was dark and the open-field environment was illuminated from above by a 60 W white light. The 
subject was placed in the center of the box to begin a 5-minute test session. The test was video 
recorded from above. The number of squares that the subject moved into, operationalized as 
having at least the front two paws in the square, was scored post hoc using video tracking 
software (EthoVision, Noldus). Between each trial, the open-field environment was wiped down 
with the disinfectant Nolvasan to eliminate any olfactory cues. Baseline activity was measured 3 
days prior to injury. Open field activity was assessed 2, 9, and 19 days post injury. Decreased 
activity in the open field, compared to baseline, was interpreted as an indication of depression-
like behavior. 
Burrowing 
The burrowing task is a behavioral test developed by Deacon et al. (2006) that was initially used 
to screen for prion disease in mice and IL-1β-expressing replication-deficient adenovirus in rats. 
Normal rats demonstrate vigorous burrowing activity, which suggests that it is a rewarding 
activity (Deacon et al., 2006). Therefore, burrowing may be a useful measure for depressive-like 
symptoms of diminished pleasure or loss of energy in subjects (Deacon et al., 2006).  
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The burrowing apparatus was a polyvinyl chloride (PVC) tube [45 (length) x 15 (diameter) cm] 
closed on one end. Each subject was assigned a separate apparatus and testing was conducted in 
the subjects’ home cage. To begin testing, pre-weighed burrowing tubes were filled with 
approximately 500g of pine wood chips and placed in the subject’s cage. After 2 hours the 
woodchips burrowed out of the tube were weighed. The burrowing apparatus was not disinfected 
between trials of the same subject in order to prevent the burrow from appearing foreign to the 
subject. Baseline burrowing scores were measured 2 days prior to injury. After injury, burrowing 
was assessed on days 2, 10, and 20 days post injury. Decreased burrowing, as compared to 
baseline, was interpreted as an indication of depression-like behavior. 
Social exploration 
Rats are highly sociable creatures (McKibben et al., 2014), and a decrease in social interaction is 
indicative of decreased interest or pleasure. Social exploration was assessed in the open-field 
environment described above. A subject was placed in the center of the open-field and allowed to 
explore for 5 minutes. A rat (<250 g weight) not exposed to any experimental treatment was then 
placed in the open field as far from the test subject as possible. The subject and the social 
exploration rat were videotaped for 5 minutes. Time spent performing social (moving toward, 
anogenital sniffing, close following) and nonsocial behavior (resting, moving away, self-
grooming, and exploration of the open field) was scored by two independent observers as 
described previously by Swain and Le (1998). 
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Forced swim test 
The forced swim test (FST) is commonly used for assessing depression in rodent models (Posolt, 
1977). For the test, subjects are placed into a plastic container filled with water from which they 
cannot escape. If an animal is not depressed, it will be mobile throughout the test. However, if a 
subject has depressive symptoms it will remain immobile throughout some portion of the test. 
The duration of this immobility is interpreted as a measure of behavioral despair or 
“hopelessness.” Hopelessness has been positively correlated with suicide ideation, one of the 
major criteria of depression (Minkoff et al., 1973).  
For this test, subjects were allowed to acclimate to the testing room for 10 minutes. The testing 
room was maintained at 27.2˚C. The subject was then placed in a clear rectangular container [57 
(Length) x 40 (Width) x 33 (Height) cm] filled with water, maintained at 23 ± 1˚C. The forced 
swim test is traditionally conducted using a 10-minute acclimation period and a 5-minute test 
period 24 hours later. However, Abel and Bilitzke (1990) found that immobility measured in 10-
minute acclimation period was highly correlated with immobility measured in a 5-minute test 
period conducted 24 hours later. Therefore, acclimation was not performed, and the testing 
period consisted of the first 10-minute exposure to the inescapable water environment. The test 
was video recorded from above and time spent immobile was scored by two independent 
observers. Care was taken to ensure high inter-rater reliability. Immobility was characterized as a 
lack of any movement except those required to keep the head above water (Porsolt et al., 1977). 
Locomotor recovery 
The recovery of hind limb stepping ability was scored using the Basso, Beattie and Bresnahan 
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(BBB) scale (Basso et al., 1995). Briefly, subjects were placed in an open-field enclosure (99 cm 
diameter, 23 cm deep) and allowed to move freely. Because rats often freeze when first 
introduced to a new environment, they were acclimated to the open field test area prior to surgery 
for 5 minutes on 3 consecutive days. After injury, the locomotor capacity (BBB) of subjects was 
observed for 5 minutes and scored by a trained observer on days 1-7, 9, 11, 13, 15, 18, 21, 24, 
and 27 post-SCI. Care was taken to ensure that all investigators’ scoring behavior had high intra- 
and inter- observer reliability (all r’s > 0.89) and that they were blind to the subject’s 
experimental treatment. 
Sensory reactivity 
Thermal reactivity was assessed using radiant heat in the tail-flick test. Subjects were placed in 
the restraining tubes with their tail positioned in a 0.5 cm deep groove, cut into an aluminum 
block, and allowed to acclimate to the apparatus (IITC Inc., Life Science, CA) and testing room 
(maintained at 26.5 °C) for 15 min. Thermal thresholds were then assessed. Thermal reactivity 
was tested using a halogen light that was focused onto the rat’s tail. Prior to testing the 
temperature of the light, focused on the tail, was set to elicit a baseline tail-flick response in 3-4 s 
(average). This pre-set temperature was maintained across all subjects. In testing, the latency to 
flick the tail away from the radiant heat source (light) was recorded. If a subject failed to 
respond, the test trial was automatically terminated after 8 s of heat exposure. Two tests occurred 
at 2-min intervals, and the second test tail-flick latencies were recorded. To confirm that subjects 
did not respond in the absence of the heat stimulus, blank trials were also performed. A ‘false 
alarm’ was recorded if subjects made a motor movement or vocalization response during the 
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blank tests. The blank trials were performed 1 min before or after each sensory test (in a 
counterbalanced fashion). No false alarms were recorded. After assessment of thermal reactivity, 
subjects were returned to their home cages for a minimum of 2 h. 
After 2 h, subjects were placed back into restraint tubes and presented with von Frey stimulation 
(von Frey stimuli formed from nylon monofilaments; Semmes–Weinstein Anesthesiometer, 
Stoelting Co., Chicago, IL) to test tactile reactivity. Filaments of increasing strength were applied 
every 2 s to the plantar surface of the paw. The stimuli was presented until subjects exhibited a 
paw withdrawal/motor and vocalization response. The intensity of the stimuli that produced the 
responses was reported using the formula provided by Semmes–Weinstein: Intensity = log10 
(10,000 * g force). If one or both responses were not observed, testing was terminated at a force 
of 300g. Each subject was tested twice on each foot in a counterbalanced ABBA order. 
Statistical analysis 
For the identification of depression, first a Principal components analysis (PCA) was used to 
determine which behavioral measures were correlated with each other. PCA is a variable 
reduction technique that transforms a group of observations from a related set of variables into a 
(typically) smaller set of linear uncorrelated variables. These uncorrelated variables are referred 
to as principal components. Change from baseline (Test day score- Baseline score) scores for 
each of the subjects on each of the behavioral measures (sucrose preference, forced swim, open 
field activity, social exploration, burrowing, food deviation change) were averaged across days 
9/10 and 19/20 and then subjected to a principal components analysis using orthogonal Varimax 
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rotation. Scores were averaged so that the equation derived in subsequent analyses would 
characterize symptoms that persisted into the chronic phase as well as having strong predictive 
value for the early phase of SCI. Factors with loadings of ≥ 0.32 on a component were retained 
and used in subsequent cluster and discriminant function analyses. Variables with a complex 
structure, which loaded onto more than one component, were removed from the PCA and the 
analysis was repeated (Tabachnick and Linda, 2007).  
A hierarchical cluster analysis was then performed using the measures with moderate-strong 
loadings on the components retained in the PCA. Hierarchical cluster analysis is a statistical 
procedure used to separate a sample into clusters that the experimenter can operationally define. 
Average change from baseline scores (derived from both Days 9-10 and 19-21), on each of the 
retained behavioral tests, were used in this test. The hierarchical cluster analysis was performed 
using Ward’s method and applying squared Euclidean distance as the distance measure. The 
number of appropriate clusters, based on the behavioral measures, was obtained by looking for a 
break in the agglomeration coefficient change and by observing the dendrogram, which visually 
depicts the distance between linked clusters. It must be noted that the cluster sizes need not be 
even. After identifying the number of clusters depicted in the dendogram, the cluster analysis 
was repeated using the same parameters but requesting a single solution of two clusters. A new 
variable, cluster membership, was generated for all subjects.  
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The two clusters’ performance on each of the behavioral measures collected (depression and 
recovery) were compared across the recovery period (days 9-10 and 19-20), after any potential 
antidepressant effects of S-ketamine should have been dissipated. Repeated measures analysis of 
variance (ANOVA) tests were conducted using change from baseline scores (Test day score- 
Baseline score) for each of the behavioral tests. Based on the pattern of behaviors exhibited by 
each cluster, they were labeled as “depressed” and “non-depressed.”  
Repeated-measures ANOVAs were also used to compare the locomotor and sensory recovery 
across S-ketamine dose groups and across depressed and non-depressed subjects. First, BBB 
scores were transformed to help assure that the data were amendable to parametric analyses 
(Ferguson, et al. 2004). This transformation pools BBB scores 2–4, removing a discontinuity in 
the scale. The transformation also pools scores from a region of the scale (scores 14–21) that is 
very seldom used under the present injury parameters. By pooling these scores, we obtain an 
ordered scale that is relatively continuous with units that have approximately equivalent interval 
durations. Meeting these criteria allows us to apply metric operations (computation of mean 
performance across legs), improves the justification for parametric statistical analyses, and 
increases statistical power. Additional statistical power was achieved by obtaining a measure of 
locomotor performance 24 h after injury, prior to shock treatment. This provides a behavioral 
index of the injury extent that is correlated with long-term recovery (r>0.41, p > 0.05; Hook et 
al., 2004). By using this factor as a covariate in an analysis of covariance (ANCOVA), we 
substantially reduce unexplained variance. Group differences on dichotomous variables (e.g., 
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mortality) were evaluated using the Fisher exact probability test. This test allows for 
comparisons of simple (2 x 2) frequency tables with relatively small samples.  
We also examined the effects of S-ketamine using ANOVAs, with S-ketamine dose as the 
dependent variable. Remaining within the window of S-ketamine’s efficacy, we analyzed data 
collected on day 2 post-SCI. Next, using the depressed and non-depressed clusters that we 
obtained from day 9-10 and 19-20, we used multivariate ANOVA’s to find any significant 
interactions between dose and depression on day 2 post-SCI.  
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CHAPTER III 
RESULTS 
Effects of S-ketamine on sensory and motor recovery 
Recognizing that changes in motor and sensory function may confound performance on the tests 
of depression, our initial analyses focused on the effects of S-ketamine on sensory reactivity and 
recovery of locomotor function.  
Analgesic efficacy of S-ketamine  
As shown in Figure 2, a single dose of S-ketamine (i.p.) produced robust analgesia on both the 
thermal and tactile reactivity tasks. Using baseline reactivity (prior to treatment, time 0 min) as a 
covariate, there was a significant main effect of dose on the tail-flick test (F (3, 33)= 8.27, p < .
001) as well as the motor response to tactile stimulation (F (3, 33)= 3.48, p = .03). Planned 
comparisons indicated that the 20 mg/kg of S-ketamine produced significant analgesia, relative 
to vehicle controls on all tasks (Tail flick, F (1, 13) =16.73, p < .001; Tactile motor, F (1, 13) 
=7.63, p < .02; Tactile vocal, F (1, 13) = 7.25, p < .02).  
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 Figure 2. Subjects receiving 20 mg/kg S-ketamine displayed significant analgesia for 60-180 
mins post administration on all sensory reactivity tasks, relative to vehicle controls. Prior to 
S-ketamine administration, there were no differences in motor or vocal reactivity across 
dose groups. Following administration of 20 mg/kg S-ketamine, however, subjects showed 
decreased motor reactivity to a thermal (A) and mechanical (B) stimulus for 180 mins post 
administration. Decreased vocal reactivity to mechanical stimulation was also observed for 
the 20 mg/kg group for 60 mins post S-ketamine administration (C). **p < 0.05.  
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Recovery of locomotor function 
There was no effect of S-ketamine on the recovery of locomotor function (F (3, 28) < 1.0, p > 
0.05). Baseline BBB scores were balanced across dose groups and final BBB scores ranged from 
8 ± 1.02 for the 0 mg/kg dose group to 9.125 ± .63 for the 5 mg/kg and 20 mg/kg group (Figure 
3).  
Figure 3. S-ketamine had no effect on locomotor recovery. BBB scores were balanced prior 
to administration and, irrespective of dose, all groups recovered similar levels of locomotor 
function.  
Recovery of sensory function 
ANOVAs were used to examine the effects of S-ketamine dose on long-term recovery of sensory 
function. Acute administration of S-ketamine significantly affected tail-flick latency on day 21 
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post-injury (F (3, 31) = 3.11, p < .05). Further comparisons revealed that the 5 mg/kg group 
displayed significantly longer tail-flick latencies than all other groups at this timepoint (Fig. 4A). 
The dose of S-ketamine did not affect tail-flick latencies on Days 3 or 11 post injury. There were 
also no effects of S-ketamine dose on motor reactivity thresholds with mechanical stimulation 
across the 21-day recovery period. However, vocal response thresholds differed across groups on 
Day 21 (F (3, 31) = 3.99, p < .05).  Both the 0 and 5 mg /kg displayed higher vocal reactivity 
thresholds than the 10 mg/kg group at this time point (Fig. 4B).   
!  
Figure 4. The 5 mg/kg dose of S-ketamine decreased reactivity to both thermal (A) and 
mechanical (B) stimuli 21 days after administration. ** p< .05. 
Depression following spinal cord injury 
To characterize subjects as depressed or not-depressed, initial analyses focused on symptoms of 
depression measured on Days 9-11 and 19-21 post-injury, after any anti-depressant effects of the 
S-ketamine should have dissipated. 
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First, a principal components analysis (PCA) was used to assess the validity of the individual 
tests for identifying symptoms of depression. Using the PCA, two principal components were 
identified. The first component contained burrowing activity and food deviation, while forced 
swim and open-field activity loaded on the second component. Sucrose preference and social 
activity loaded on both components, and were removed from further cluster analyses.   
Table 2. Rotated using orthogonal Varimax rotation with Kaiser normalization. Only 
component loadings ≥ 0.32 are shown.   
Principal Component Loadings 
Average change from baselines scores obtained for days 9-10 and 19-20, for each of the 
behavioral tasks retained in the PCA, were used in a hierarchical cluster analysis (HCA). The 
HCA was used to classify the subjects into depressed and non-depressed groups. The dendogram 
Behavioral Test Component 1 Component 2
Burrow Activity -.783
Food Deviation .769
Forced Swim Test .734
Open-Field Activity
-.594
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produced by the analysis identified two subject cohorts, with 19 subjects in the first cluster and 
13 in the second.  
 
 
!  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Depressed
Non-­‐Depressed
Figure 6. The dendogram shows the result of the hierarchical cluster analysis.  
Two clusters were formed based on depression-like behaviors that persisted across the 
acute and chronic phases of injury. 
Individual ANOVAS were used to examine differences between the two clusters on Days 9 and 
19. All results are portrayed as a change from baseline (Figs 7A-F). As shown in Fig. 7A, 
subjects in Cluster 2 displayed a larger decrease in sucrose preference on Day 9 post-injury 
relative to Cluster 1. The differences between the cohorts, however, only approached significance 
(F (1, 31) = 3.16, p= .06). Sucrose preference did not differ across clusters on Day 19 post-
injury. As shown in Fig. 7B, open field activity was also significantly different between the two 
clusters on days 9-10 and 19-20 (F (1, 31) = 22.9 and 33.8 respectively, p < .05). Cluster 2 
showed significantly decreased open field activity on both days when compared to Cluster 1 
subjects. Burrowing scores were not significantly different between the two clusters at either 
timepoint (F (1, 31) = 0.02, 1.04 respectively, p > .05) although, as can be seen in Fig. 7C, 
Cluster 2 showed decreased burrowing activity on days 19-20 when compared to Cluster 1. 
Similarly, social activity did not differ significantly between the clusters (F (1, 31) < 1.0 for both 
timepoints, p > 0.05). Subjects in Cluster 2 subjects showed higher social activity on days 9-10, 
while Cluster 1 subjects showed increased social behavior on days 19-20 (Fig. 7D). Food 
deviation between the two clusters did not differ significantly (F (1, 31) < 1.0 for both 
timepoints, p > .05; Fig. 7E). Cluster 2 subjects displayed comparatively more mobility in the 
forced swim test than subjects in Cluster 1, however these results were not significant (F (1, 31) 
=2.13, p > .05). Based on lower average burrowing activity, decreased sucrose preference and 
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decreased open-field activity, subjects in Cluster 2 were designated as “depressed,” while Cluster 
1 was “non-depressed.” Therefore 13 of 32 subjects (41%) were found to show signs of 
depression or depression-like behavior.  
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Figure 7. Subjects categorized as depressed displayed behavioral changes indicative of 
anhedonia and fatigue. Relative to non-depressed subjects, depressed subjects had 
decreased sucrose preference (A), burrowing behavior (B) and open field activity (C) on 
Days 9-10 and 19-20 post injury. Social activity (D), food deviation (E) and immobility in 
the forced swim test (F) did not differ across the groups. All data is shown as change from 
baseline. **p< .05. 
Effects of depression on locomotor and sensory recovery 
Recovery of locomotor function 
There were no significant differences between the depressed and non-depressed groups in 
locomotor recovery (F (3, 28) = . 123, p > .05). (Fig. 8). Final BBB scores were 9.18 ± .49 for 
the non-depressed group, and 8 ± .54 for the depressed group. 	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Figure 8. Locomotor recovery did not differ significantly between depressed and non-
depressed subjects.  
Recovery of sensory function 
Tactile and tail flick tests were used to assess long-term recovery of sensory function in the 
depressed and non-depressed groups. Prior to treatment, there were no significant differences 
across the groups on any of the sensory reactivity tasks. Similarly, the depressed and non-
depressed groups did not differ on the tail-flick test at 21 days post-injury (F (1, 31) = .456, p > .
05; Fig. 9A). Using repeated measures ANOVAS, however, we found significant differences 
between the depressed and non-depressed groups on Day 11 for both tactile motor and vocal 
reactivity. At Day 11 post injury depressed subjects, overall, displayed higher motor and vocal 
reactivity thresholds (F (1, 30) = 9.71 and 9.60, respectively, p < .05) with mechanical 
stimulation than non-depressed subjects (Fig. 9B and C, respectively).  
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Figure 9 (A-C). Depressed subjects show higher motor and vocal thresholds on Day 11 post 
injury compared to non-depressed subjects. ** p < 0.05.  
Effects of S-ketamine on depression 
After identifying the depressed and non-depressed cohorts, we examined the effects of S-
ketamine on depression-like behaviors. The incidence of depression, assessed on Days 9-10 and 
19-20, was equal across the four S-ketamine dose groups (Fig. 10). At this point, however, any 
potential antidepressant effects of S-ketamine would have dissipated (Murrough et al., 2013). 
Analyzing the behavioral data collected on Day 2 post-injury, and within the clinical window for 
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S-ketamine’s efficacy, we first compared the expression of depression-like behaviors across dose 
groups, and then using multivariate ANOVAS looked at potential interactions between S-
ketamine and depression. 
Figure 10. The graph shows the number of depressed and non-depressed subjects within 
each treatment group. 
Analysis of Day 2 data for sucrose preference showed no significant differences between the 
drug treatments (F (3, 31) = .691, p > .05). Depression, however, did significantly impact sucrose 
preference scores on Day 2 (F (1, 31) = 4.56, p < .05). While the subjects later categorized as 
depressed displayed a large decrease in sucrose preference on Day 2, relative to baseline, the 
non-depressed subjects did not (Fig. 11A).  
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There were no significant differences in burrowing activity on Day 2 between the dose treatment 
groups (F (3, 31) = .002, p > .05). However, there was a significant interaction between 
depression and drug treatment for burrowing behavior (F (3, 31) = 4.93, p < .05). The 5 and 10 
mg/kg doses of S-ketamine appeared to decrease burrowing behavior on Day 2 post-injury, 
relative to baseline, in the depressed subjects whereas these doses increased burrowing behavior 
in the non-depressed subjects. 
There were no effects of dose on open field activity on Day 2 post-injury (F (3, 31) = 1.52, p > .
05). However, there were significant differences between depressed and non-depressed subjects 
at this timepoint (F (1, 31) = 5.76, p = .023).  Depressed subjects displayed lower open field 
activity across all dose treatments relative to non-depressed subjects (Fig. 11C).  
Neither drug dose nor depression significantly affected social behavior on Day 2 post injury 
(drug dose, F (3, 31) = 2.58, p = .077; depression, F (3, 31) = 0.518, p > .05). However, as 
shown in Fig. 11D, subjects that received 20 mg/kg of S-ketamine displayed comparatively more 
social behavior than the other dose groups. Planned comparisons confirmed that social behavior 
in the 20 mg/kg groups was significantly higher than that displayed by the 0 and 10 mg/kg dose 
groups (p< .05). Although not biologically active at 24 hrs post administration, the 20 mg/kg 
dose of S-ketamine appears to have protracted effects on depression; 20 mg/kg S-ketamine 
increased social interactions in the depressed cohort relative to all other groups. 
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Figure 11. S-ketamine (20 mg/kg) increased social behavior on Day 2 post injury. Twenty-
four hours after administration, ketamine appears to decrease the effects of depression on 
sucrose preference (A) and the 20 mg/kg dose reversed effects on the social interaction task. 
None of the doses of S-ketamine tested affected burrowing (B) or open field activity (C). ** 
p <.05 
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CHAPTER IV 
CONCLUSION 
 Based on the battery of tests performed and subsequent statistical analysis, we found that 41% .
of our subjects were depressed. Depression-like behavior was associated with lower average 
burrowing activity, decreased sucrose preference and decreased open-field activity on days 9-10 
and 19-20 post-SCI. The administration of S-ketamine initially reversed symptoms of 
depression. Analyzing data collected on day 2 post-injury, and within the window for S-
ketamine’s efficacy, we found that 20 mg/kg S-ketamine increased social behavior, relative to all 
other dose groups. Importantly, depressed subjects treated with 20 mg/kg S-ketamine showed the 
highest level of social interaction 24 hours after administration. These data suggest that S-
ketamine may be an effective antidepressant after SCI.  
The incidence of depression found in our study is commensurate with that reported for the 
clinical SCI population. Although only 11-24% of patients are diagnosed with MDD after injury 
(Krause et al., 2000), 37 % of patients display significant symptoms of depression after SCI 
without meeting the criteria for MDD (Migliorini et al., 2009). In our study, 13 of the 32 subjects 
displayed characteristics of depression on some, but not all, tasks. Characterization of depression 
in this study therefore is more akin to the patients that have depression symptoms but are not 
diagnosed with MDD. Further, other SCI studies conducted in rodent models have shown a 35% 
depression rate, similar to ours (Luedtke et al., 2014). Unfortunately, S-ketamine did not affect 
the development of depression-like behaviors. As shown in Fig.9 the incidence of depression was 
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similar across the four S-ketamine dose groups on Days 9-21. Even though the literature suggests 
that the effects of a single dose of ketamine post SCI are long-lasting (Young, 2013; Salvadore 
and Singh, 2013) the effectiveness of S-ketamine would not have persisted over 21 days. Indeed, 
the established terminal elimination half-life of ketamine is 100-200 minutes (Niciu et al., 2014), 
therefore it would not have been biologically active at these later stages of injury.  Our data, 
therefore, suggest that S-ketamine affects the expression rather than the development of 
depression.  
Indeed, in our study S-ketamine did reverse symptoms of depression 24 hours after drug 
administration, which was evident in the social behavior task. This finding is significant, as 
social behavior is the most salient symptom for the human population. Studies conducted in the 
human population have shown that at 24 hours post administration, a single dose of ketamine 
produces an antidepressant response rate of 64%, compared to 28% in controls treated with the 
anesthetic midazolam (Murrough et al., 2013). These antidepressant effects appear to subside by 
Day 7 (Murrough et al., 2013). Notably, however, Murrough (2013) also reported some adverse 
side effects with ketamine administration, including dizziness, blurred vision, headache, attention 
deficits, and poor coordination. Furthermore, 17% of the patients experienced significant 
dissociative symptoms immediately after infusion (Murrough, 2013). Another study tested the 
effects of repeated infusions of ketamine, and showed that the response duration was much 
greater than that of a single infusion (aan het Rot et al., 2010). This study only involved patients 
that had positively responded to single infusions of ketamine in the past, however, and was 
severely limited by a small sample size (n=9). In addition, the duration of effective remission of 
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symptoms varied across patients; ranging from a relapse for less than 1 week post-treatment, to 
remaining symptom-free for more than 3 months (aan het Rot et al., 2010). Further experiments 
need to be conducted to determine the long-term efficacy of S-ketamine with repeated infusions, 
in addition to establishing the dose of S-ketamine that is safe and has limited side effects. 
Importantly, S-ketamine had no effects on locomotor recovery, sensory function or long-term 
neuropathic pain in our study. In fact, studies have shown that S-ketamine administered in the 
acute phase of SCI exerts neuroprotective effects in rats, by reducing levels of tumor necrosis 
factor α (TNF- α), interleukin-6 (IL-6), spinal cord malondialdehyde (MDA), and TUNEL-
positive cells (Kose et al., 2013). This is in contrast to, currently prescribed selective serotonin 
reuptake inhibitors (SSRI) that have side effects that can include attenuation of functional 
recovery, as well as a paradoxical potentiation of symptoms of depression (Coyle et al. 2015). It 
is important to develop treatment strategies that reduce symptoms of depression without 
compromising functional recovery for SCI. S-ketamine may be a viable treatment option. 
S-ketamine also appeared to be analgesic while biologically active. A clinical study looking at 
neuropathic pain below the level of spinal cord injury reported that 50% of patients responded 
positively to S-ketamine treatment, compared to 0% in a placebo group and 10% in a lidocaine-
treated group (Kvarnström et al., 2004). In addition, S-ketamine administration did not change 
temperature thresholds or affect sensory function (Kvarnström et al., 2004). In our study, 
depression also reduced pain in the early phase of injury. Specifically, the 20 mg/kg dose reduced 
evoked pain on the thermal and tactile tasks for up to 180 minutes.  For chronic pain, whereas 
non-depressed subjects appeared to develop mechanical sensitivity across the days post injury 
(with a decrease in mechanical thresholds), depressed subjects showed no change in motor or 
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vocal thresholds. These effects run counter to most empirical studies. Pain is usually comorbid 
with depression (Korff and Simson, 1996). Further data is needed to conclusively determine the 
relationship between pain, depression and S-ketamine in our rodent model.   
Our data suggest that S-ketamine may be an effective antidepressant with limited side-effects 
after SCI.  Further studies are warranted, investigating the effects of multiple infusions and 
alternate routes of administration (i.e. intravenous to emulate the clinical setting more closely). 
The results are promising. This alternative antidepressant may be effective for treating 
depression not only after SCI, but also for the10-30% of depressed patients that do not achieve 
remission with available antidepressants	  (Rush et al. 2006; Mathew & Charney, 2009; 
Holtzheimer & Mayberg, 2010). 
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